永安药业涨2.00%，成交额1.20亿元，主力资金净流入1027.41万元

Group 1 - The core viewpoint of the news is that Yong'an Pharmaceutical has shown significant stock performance, with a year-to-date increase of 125.80% and a recent price of 17.82 CNY per share, reflecting strong market interest and trading activity [1][2] - As of October 31, the number of shareholders for Yong'an Pharmaceutical is 57,100, a decrease of 4.28% from the previous period, while the average circulating shares per person increased by 4.48% to 4,296 shares [2] - The company operates primarily in the pharmaceutical sector, focusing on the research, production, and sales of taurine products, which account for 64.14% of its main business revenue [1][2] Group 2 - For the period from January to September 2025, Yong'an Pharmaceutical reported a revenue of 577 million CNY, a year-on-year decrease of 6.72%, and a net profit attributable to the parent company of 25.5 million CNY, down 58.78% year-on-year [2] - The company has distributed a total of 401 million CNY in dividends since its A-share listing, with 87.7 million CNY distributed over the past three years [3]